ArticleACR open rheumatology2023

Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.

Dennis McGonagle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.